Research programme: nausea and vomiting therapeutics - SolvayAlternative Names: SLV 323
Latest Information Update: 10 Jul 2007
At a glance
- Originator Solvay Pharmaceuticals
- Mechanism of Action Neurokinin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 25 Nov 2003 Preclinical trials in Nausea and vomiting in Belgium (unspecified route)